With approximately 34 million infected individuals in the year 2011, the HIV pandemic keeps being a worldwide problem. Due to its essential role in the infection, the viral envelope protein gp120 is a highly interesting target for use as research reagent or even as component of an eventual vaccine. The preparation of pure protein by fermentation of gentically modified cells and consecutive purification are common processes in the pharmaceutical industry. Highly specific purification steps like immunoaffinity chromatography are of great advantage. This process utilizes the specific binding of an antibody to its antigen. In the year 2009 Polymun Scientific offered two gp120-specific antibodies in the portfolio which were tested on suitability in this type of chromatography. It could be shown that both antibodies, namely B12 and 2G12 can be used as ligands for the chromatography. However, due to the better dynamic binding capacity of the 2G12 column this antibody should be favoured.